

Below is a list of all poster sessions by members of the Ludwig community at the AACR 2023 Annual Meeting.

Poster session date	Session title	Session type - Location	Poster title	Ludwig location	Presenter/Ludwig PI	Session time (U.S. EDT)
4/16/23	Session PO.IM02.02 - Cancer-associated Inflammation and Microbiome	Section 22	646 / 19 - Characteristics of skin microbiome in immune related cutaneous adverse events	Ludwig Weill Cornell	Lukas Kraehenbuehl/Taha Merghoub	1:30-5:00
4/16/23	Session PO.TB10.02 - Tumor Heterogeneity 2	Section 5	137 / 18 - Epigenetic regulation of APOBEC3A mutagenesis and tumor evolution during targeted therapy in non-small cell lung cancer	Ludwig Harvard	Hideko Isozaki/Aaron Hata	1:30-5:00
4/16/23	Session PO.IM01.14 - Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies	Section 24	682 / 2 - Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model	Ludwig Oxford/Brussels	Emily Steffke/Benoit Van den Eynde	1:30-5:00
4/16/23	Session PO.MCB05.01 - Targeting Replication Stress and the Immune Microenvironment	Section 11	299 / 1 - Large tandem duplications in cancer resulting from transcription and DNA replication collisions	Ludwig Chicago	Yang Yang/Lixing Yang	1:30-5:00
4/16/23	Session PO.CL01.14 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	Section 42	1024 / 1 - Improved cfDNA methylation profiling through correction of misrepaired jagged-ends	Ludwig Stanford	Rui Wang/Maximilian Diehn, Ash Alizadeh	1:30-5:00
4/16/23	Session PO.CL01.14 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1	Section 42	1045 / 22 - RePhyNER: Overcoming limitations of access to matched germline for serial liquid biopsy applications	Ludwig Stanford	Mohammad Shahrokh Esfahani/Maximilian Diehn, Ash Alizadeh	1:30-5:00
4/16/23	Session PO.CL01.01 - Biomarkers of Therapeutic Benefit 1	Section 39	959 / 10 - Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients	Ludwig Stanford	Sneha Ramakrishna/Crystal Mackall, Michelle Monje	1:30-5:00
4/17/23	Session PO.ET03.05 - Novel Mechanisms / Drug Transport and Metabolism	Section 19	1696 / 21 - Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer	Ludwig Harvard	Bogang Wu/Leif Ellisen	9:00 AM - 12:30 PM
4/17/23	Session PO.CL07.12 - Modifiers of the Tumor Microenvironment	Section 45	2343 / 24 - Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma	Ludwig Harvard	Jun Ren/Rakesh Jain	9:00 AM - 12:30 PM
4/17/23	Session LBPO.IM01 - Late-Breaking Research: Immunology 1	Section 35	LB095 / 11 - Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen	Ludwig Johns Hopkins	Brian Mog/Bert Vogelstein, Shubin Zhou	9:00 AM - 12:30 PM
4/17/23	Session PO.CT02.01 - Phase II Clinical Trials 1	Section 47	CT142 / 4 - TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC)	Ludwig Harvard	Filipa Lynce/Jennifer Guerrero	1:30 PM - 5:00 PM
4/17/23	Session PO.TB11.08 - Tumor-Host Interactions and Disease Progression	Section 6	2517 / 25 - Optimizing breast cancer therapy by inhibiting the adenosine receptor and oxygen consumption	Ludwig Weill Cornell	Sadna Budhu/Taha Merghoub	1:30-5:00
4/17/23	Session PO.IM02.01 - Cancer-associated Immunosuppression	Section 21	2890 / 28 - Investigating dynamic IDO-Kyn-Ahr pathway induced tumor immunosuppression using imaging modality to optimize therapeutic intervention	Ludwig Weill Cornell	Mamadou Alpha Bah/Taha Merghoub, Jedd Wolchok	1:30 PM - 5:00 PM
4/17/23	Session PO.TB11.08 - Tumor-Host Interactions and Disease Progression	Section 6	2513 / 21 - Distinct cancer-intrinsic mechanisms mediate nerve recruitment/outgrowth versus perineural invasion	Ludwig MIT	William L. Hwang/Tyler Jacks	1:30 PM - 5:00 PM
4/17/23	Session PO.BCS01.01 - Bioinformatics Applications in Cancer Biology 2	Section 32	3136 / 22 - HYENA detects non-coding genes activated by distal enhancers in cancer	Ludwig Chicago	Anqi Yu/Lixing Yang	1:30 PM - 5:00 PM
4/17/23	Session LBPO.CL01 - Late-Breaking Research: Clinical Research 1 / Endocrinology	Section 34	LB131 / 14 - Association between epigenetic heterogeneity of esophageal adenocarcinoma and response to first-line immunotherapy in LUD2015-005 Trial	Ludwig Oxford	Phil Xie/Xin Lu	1:30 PM - 5:00 PM
4/17/23	Session PO.CL01.16 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3	Section 43	3375 / 18 - Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq	Ludwig Stanford	James Isbell/Ash Alizadeh, Maximilian Diehn	1:30 PM - 5:00 PM
4/17/23	Session PO.CL09.02 - Molecular Targeted Therapies 1	Section 44	3403 / 13 - Leveraging a p53 "super-tumor suppressor" to understand mechanisms of lung adenocarcinoma regression	Ludwig Stanford	Mengxiong Wang/Laura Attardi	1:30 PM - 5:00 PM
4/17/23	Session PO.BCS01.05 - Integrative Computational Approaches and Analyses	Section 33	3165 / 18 - ImmuneSig: A deep learning framework to develop gene expression signature of immune checkpoint inhibitor therapy	Ludwig Harvard	Yang Liu/Franziska Michor	1:30 PM - 5:00 PM
4/18/23	Session PO.MCB07.03 - Gene Regulation in Cancer	Section 9	3717 / 3 - Defining the mechanism of ER receptor transcription complex activity and its effect on epigenetic modulations using super resolution microscopy	Ludwig Harvard	Tara Akhshi/Myles Brown	9:00 AM - 12:30 PM
4/18/23	Session PO.ET03.04 - Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance	Section 16	3894 / 13 - The role of ELF3 in acquired resistance to endocrine therapy in ER-positive breast cancer	Ludwig Harvard	Na Zhang/Myles Brown.	9:00 AM - 12:30 PM
4/18/23	Session PO.ET03.03 - Drug Resistance in Molecular Targeted Therapies 3	Section 15	3875 / 25 - Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC	Ludwig Harvard	Delia Margaret Friel/Myles Brown	9:00 AM - 12:30 PM
4/18/23	Session LBPO.CL02 - Late-Breaking Research: Clinical Research 2	Section 35	LB202 / 17 - Obesity-trained C1q+ macrophages compromise T cell anti-tumor immunity	Ludwig Harvard	Tao Zhang/Myles Brown.	9:00 AM - 12:30 PM
4/18/23	Session PO.CL01.04 - Biomarkers of Therapeutic Benefit 4	Section 37	4353 / 28 - Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacituzumab Govetican in localized TNBC	Ludwig Harvard	Nicole Peiris/Leif Ellisen	9:00 AM - 12:30 PM
4/18/23	Session PO.MCB09.01 - Cancer and Metabolism 1	Section 7	3680 / 11 - Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy	Ludwig Harvard	Zuen Ren/Leif Ellisen	9:00 AM - 12:30 PM
4/18/23	Session PO.ET03.03 - Drug Resistance in Molecular Targeted Therapies 3	Section 15	3867 / 17 - Chromatin modification driving subclonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer	Ludwig Harvard	Chendi Li/Aaron Hata	9:00 AM - 12:30 PM
4/18/23	Session PO.ET03.03 - Drug Resistance in Molecular Targeted Therapies 3	Section 15	3868 / 18 - Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer	Ludwig Harvard	Chendi Li/Aaron Hata	9:00 AM - 12:30 PM

4/18/23	Session PO.CL07.06 - Inflammation, Immunity, and Cancer	Section 41	4462 / 15 - Immunoregulatory effects of NNMT-expressing cancer-associated fibroblasts	Ludwig Chicago	Janna Heide/Ernst Lengyel	9:00 AM - 12:30 PM
4/18/23	Session PO.TB11.01 - Signaling Pathways That Impact the Tumor Microenvironment	Section 5	3655 / 29 - Exploring the role of FasL in the ovarian cancer tumor microenvironment	Ludwig Chicago	Grace Keegan/Ernst Lengyel	9:00 AM - 12:30 PM
4/18/23	Session PO.CL07.02 - Immunomodulatory Agents and Interventions	Section 40	4416 / 2 - IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy	Ludwig Harvard	Nilesh Talele/Rakesh Jain	9:00 AM - 12:30 PM
4/18/23	Session PO.MCB06.02 - Epigenetic Mechanisms as Drivers of Tumorigenesis	Section 9	4759 / 22 - Dissecting EP300 and CBP function in prostate cancer models	Ludwig Harvard	Kiran Mirpuri/Myles Brown	1:30 PM - 5:00 PM
4/18/23	Session PO.IM01.10 - Inflammation and Immunity in the Tumor Microenvironment	Section 23	5149 / 21 - Age-associated remodeling of anti-tumor T cell immunity and metabolism	Ludwig Harvard	SeongJun Han/Marcia Haigis	1:30 PM - 5:00 PM
4/18/23	Session LBPO.MCB02 - Late-Breaking Research: Molecular/Cellular Biology and Genetics 2	Section 35	LB256 / 8 - Type 1 calreticulin mutations in myeloproliferative neoplasms promote glycolysis via intracellular calcium mediated upregulation of GLUT1	Ludwig Chicago	Michele Ciboddo/Shannon Elf	1:30 PM - 5:00 PM
4/19/23	Session PO.ET06.02 - DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	Section 18	6208 / 10 - Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells	Ludwig Harvard	Jithma Prasad Abeykoon/Alan D'Andrea	9:00 AM - 12:30 PM
4/19/23	Session PO.BCS02.02 - Integrative Spatial and Temporal Multi-omics of Cancer	Section 32	6609 / 14 - Detection of rare mutations, copy number variation, and DNA methylation in the same template DNA molecules	Ludwig Johns Hopkins	Yuxuan Wang/Bert Vogelstein, Ken Kinzler	9:00 AM - 12:30 PM
4/19/23	Session PO.TB11.02 - Immunotherapy and Cellular Interactions in the Tumor Microenvironment	Section 4	5873 / 15 - LDH inhibition boosts effector T cells while destabilizing regulatory T cells and improves responses to CTLA-4 blockade	Ludwig Weill Cornell	Svena Verma/Taha Merghoub, Jedd Wolchok	9:00 AM - 12:30 PM
4/19/23	Session PO.TB11.02 - Immunotherapy and Cellular Interactions in the Tumor Microenvironment	Section 4	5877 / 19 - Intratumoral lymphocyte networks harbor TCF1+ PD1+ progenitor CD8 T cells in lung cancer	Ludwig Harvard/ Ludwig MIT	Megan Burger/Sandro Santagata, Tyler Jacks	9:00 AM - 12:30 PM
4/19/23	Session PO.IM01.06 - Immune Mechanisms Mediated by Other Therapies	Section 24	6390 / 3 - N17350 is an emerging therapeutic modality that selectively kills cancer cells and stimulates anti-tumor immunity	Ludwig Chicago	Ravindra Gujar/Lev Becker	9:00 AM - 12:30 PM
4/19/23	Session PO.CL01.13 - Spatial Proteomics and Transcriptomics 2	Section 43	6782 / 22 - Spatial transcriptomics of serous tubal intraepithelial carcinoma and its putative precursor lesions	Ludwig Chicago	Rahul Krishnan/Ernst Lengyel	9:00 AM - 12:30 PM
4/19/23	Session PO.ET06.01 - DNA Damage Response	Section 17	6190 / 19 - Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers	Ludwig Harvard	Jeffrey Patterson-Fortin/Geoffrey Shapiro	9:00 AM - 12:30 PM
4/19/23	Session PO.ET06.02 - DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others	Section 18	6210 / 12 - Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models	Ludwig Harvard	Jie Hao/Geoffrey Shapiro	9:00 AM - 12:30 PM
4/19/23	Session PO.MCB05.02 - Targeting DNA Damage Response and Novel Pathways	Section 13	6105 / 13 - Unravelling the mechanistic basis of chromoplexy, a mutational process driving early cancer genome evolution	Ludwig Harvard	Natalia Serbyn/David Pellman	9:00 AM - 12:30 PM